Accenture expands strategy capabilities in life sciences with the acquisition of bionest

New york--( business wire )--accenture (nyse: acn) has acquired bionest, a strategy and consulting firm dedicated to addressing complex strategic decisions for leading biopharma organizations across innovative areas of science including precision medicine and diagnostics, oncology, cell & gene therapy (cgt), and rare diseases.
ACN Ratings Summary
ACN Quant Ranking